Circulating microRNAs associated with tumour necrosis factor or fibloblast-like synoviocyte predict cartilage damage in early rheumatoid arthritis treated with methotrexate plus adalimumab: a subanalysis of the MIRACLE study
Authors' conclusion
Higher circulating miRNA levels predicted subsequent cartilage damage in early RA treated with a TNF inhibitor in addition to MTX.
Study context
- Population
- Patients with early rheumatoid arthritis (RA) with inadequate response to methotrexate (MTX) who started ADA
- Participants
- 134 patients
- Comparison
- Plasma miRNA levels and joint damage (mTSS) in early RA treated with ADA plus MTX (maximum tolerated vs reduced dose)
- Primary endpoint
- Association of plasma micro-ribonucleic acids (miRNAs) with increase in mTSS >0.5 points
- Follow-up
- 24 weeks
Methodological detailsopen-label, non-inferiority, logistic regression
- Open-label
- Non-inferiority
- Logistic regression
Primary result
As reported in the abstract
Association of plasma miRNA levels with mTSS increase >0.5 points
- Higher plasma miR-143-3p, miR-146a-5p, miR-21-5p and miR-221-3p significantly associated with mTSS increase >0.5 points
- Positive correlation derived from progression of joint space narrowing
Further findings
MMP-3, VEGF and IL-6 and joint destruction
- Not associated with joint destruction
Cartilage damage by MTX dose
- Occurred mainly in patients treated with reduced dose of MTX
Original publication
Circulating microRNAs associated with tumour necrosis factor or fibloblast-like synoviocyte predict cartilage damage in early rheumatoid arthritis treated with methotrexate plus adalimumab: a subanalysis of the MIRACLE study. Clin Exp Rheumatol. Published 14 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →